Q2 EPS Estimate for Oruka Therapeutics Boosted by Analyst

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Oruka from ($0.65) to ($0.59), reiterated a “Buy” rating and set a $120 price target while trimming multi‑quarter and full‑year loss forecasts for 2026–2027.
• Oruka beat expectations for its most recent quarter, reporting ($0.45) EPS versus a consensus ($0.61) loss, and currently holds a consensus analyst rating of “Moderate Buy” with an average price target near $120.80.
• The company priced an upsized $700M public offering at $72.50 per share, providing funding for development but posing near‑term dilution and potential selling pressure for existing shareholders.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities researchers at HC Wainwright raised their Q2 2026 earnings estimates for shares of Oruka Therapeutics in a note issued to investors on Wednesday, April 29th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.59) per share for the quarter, up from their prior estimate of ($0.65). HC Wainwright currently has a "Buy" rating and a $120.00 price target on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.84) EPS and FY2027 earnings at ($2.97) EPS.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16.

ORKA has been the topic of a number of other reports. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 16th. Barclays boosted their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the stock a "buy" rating in a report on Monday. Wedbush set a $165.00 price objective on Oruka Therapeutics in a research note on Monday. Finally, UBS Group boosted their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $120.80.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $68.41 on Friday. The company's 50-day moving average is $49.57 and its 200 day moving average is $36.87. The company has a market capitalization of $3.43 billion, a P/E ratio of -36.78 and a beta of -0.54. Oruka Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $91.00.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total value of $462,840.00. Following the sale, the insider directly owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,765 shares of company stock worth $1,089,745 over the last 90 days. 24.69% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fairmount Funds Management LLC increased its position in shares of Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company's stock valued at $71,252,000 after buying an additional 333,340 shares during the period. Secure Asset Management LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at about $2,475,000. Avoro Capital Advisors LLC bought a new stake in shares of Oruka Therapeutics during the third quarter valued at about $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Oruka Therapeutics during the third quarter valued at about $296,000. Finally, Commodore Capital LP increased its position in shares of Oruka Therapeutics by 23.5% during the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company's stock valued at $33,711,000 after buying an additional 333,340 shares during the period. 56.44% of the stock is currently owned by institutional investors.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised multi-quarter and full‑year EPS forecasts, trimming losses across 2026–2027 and reiterating a "Buy" rating with a $120 price target — a clear analyst vote of confidence that supports upside and reduced downside risk from earlier expected losses. MarketBeat ORKA Analyst Note
• Positive Sentiment: Oruka reported positive Phase 2a results for ORKA‑001 in plaque psoriasis (efficacy/safety readouts), which materially de-risks the lead program and strengthens the company's clinical narrative — a primary fundamental driver for biotech valuation. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
• Neutral Sentiment: Stifel Nicolaus maintained its Buy rating on ORKA, adding further broker support but without a new price target — reinforces analyst backing but is not new catalyst. Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
• Neutral Sentiment: Oruka and its clinical data are getting wider market attention (features in listicles and a Seeking Alpha slide deck), which can boost retail/institutional interest and trading volume but doesn't by itself change fundamentals. 5 Small-Cap Stocks That Are On Fire Right Now Seeking Alpha: Interim Results From EVERLAST‑A Study
• Negative Sentiment: Oruka priced an upsized $700M public offering at $72.50/share — proceeds can fund development but the deal represents potential near‑term dilution and selling pressure as shares are distributed, a common negative catalyst for existing holders. Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.